EC
AURA icon

EntryPoint Capital’s Aura Biosciences AURA Stock Holding History

EntryPoint Capital’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,300
Closed -$176K – 791
2026
Q1 		$176K Hold
26,300
– – 0.05% 662
2025
Q4 		$143K Buy
+26,300
New +$156K 0.06% 594
2024
Q3 		– Sell
-3,571
Closed -$27K – 663
2024
Q2 		$27K Sell
3,571
-4,683
-57% -$34.3K 0.01% 1212
2024
Q1 		$64.8K Sell
8,254
-14,262
-63% -$118K 0.06% 631
2023
Q4 		$199K Buy
+22,516
New +$191K 0.19% 98

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

EntryPoint Capital's AURA Position: Q2 2026 in Review

EntryPoint Capital sold out of Aura Biosciences (AURA) in Q2 2026, closing a stake of 26,300 shares — an estimated $176K sold.

EntryPoint Capital first reported a position in AURA in Q4 2023 and held it in 5 quarters. The position peaked at $199K in Q4 2023. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • EntryPoint Capital reported no remaining Aura Biosciences position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 26,300 Aura Biosciences shares in Q2 2026, an estimated $176K.
  • EntryPoint Capital first reported a position in Aura Biosciences in Q4 2023 and held it in 5 quarters.
  • EntryPoint Capital's Aura Biosciences position peaked at $199K in Q4 2023.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.